Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
BlackRock, Inc. files an amendment reporting beneficial ownership of MBX BIOSCIENCES INC common stock. The amendment states BlackRock beneficially owns 2,287,497 shares, representing 4.8% of the class. It discloses 2,246,477 shares as sole voting power and 2,287,497 shares as sole dispositive power. The filing includes Exhibit 24 and Exhibit 99 and is signed by Spencer Fleming.
MBX reports proposed and recent insider sales of Common Stock via Form 144.
The filing lists 10,423 shares tied to a broker account on 04/22/2026 and notes recent dispositions: 10,000 shares sold on 03/16/2026 for $300,471.00 and 1,061 shares sold on 03/25/2026 for $30,217.49. Several option-originated lots with grant dates are shown for the 04/22/2026 sale.
MBX Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on June 4, 2026, held via live webcast. Stockholders of record as of April 10, 2026, when 47,570,485 common shares were outstanding, may vote online, by phone, mail, or during the meeting.
Stockholders will elect two Class II directors, Patrick J. Heron and Edward T. Mathers, to serve until 2029, and vote on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. MBX paid Ernst & Young $491,678 in audit fees for 2025 and $944,548 for 2024.
The company has a classified board split into three classes and four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Medicine. As an emerging growth company and smaller reporting company, it uses scaled executive-pay disclosure. In 2025, CEO P. Kent Hawryluk received salary of $625,000, an annual cash bonus of $359,375, and option awards valued at $1,998,092, for total compensation of $2,990,867.
MBX Biosciences director Steven L. Hoerter received a stock option grant as part of his non-employee director compensation. The options have an exercise price of $27.08 per share and expire on November 21, 2035. The grant vests in equal monthly installments over one year from November 6, 2025, and was adjusted so his 2025 equity compensation does not exceed $1,000,000 in aggregate grant date fair value under the company’s director compensation policy.
MBX Biosciences, Inc. reported that director Steven L. Hoerter received a grant of stock options covering 33,751 shares of common stock. The options have an exercise price of $24.74 per share and were awarded as part of the company’s Non-Employee Director Compensation Policy.
The footnotes state that these grants were adjusted so the director’s total 2025 equity compensation does not exceed $1,000,000 based on grant date fair value under FASB Topic ASC 718. The grant vests in equal monthly installments over one year, contingent on his continued service to the company.
MBX files a Section 144 notice to sell 1,061 shares of Common Stock related to Restricted Stock Vesting that occurred on 03/23/2026.
The filing also reports a prior disposition by Richard Bartram of 10,000 shares on 03/16/2026 for $300,471. The filing names Fidelity Brokerage Services LLC as the broker and lists an account reference for the proposed sale.
MBX Biosciences, Inc. reported that Chief Financial Officer John W. Smither filed an initial Form 3 as an officer of the company. The filing lists him as Chief Financial Officer and does not report any purchases, sales, gifts, or other transactions in MBX Biosciences securities.
MBX proposed the sale of 10,000 shares of Common Stock via a Form 144 notice. The filing shows 7,500 shares from an option granted 04/20/2022 and 2,500 shares from an option granted 11/07/2022, with transactions routed through Fidelity Brokerage Services LLC on 03/16/2026. The filing lists an aggregate value of $300,470.62.
MBX Biosciences, Inc. President & CEO P. Kent Hawryluk reported an open-market purchase of 18,500 shares of Common Stock on March 13, 2026, at a weighted average price of $28.4142 per share.
The shares were bought through the P. Kent Hawryluk Revocable Trust, with prices ranging from $28.28 to $28.48 per share. Following this transaction, the trust holds 486,777 shares indirectly, and his direct holdings are reported at 728,274 shares. The filing notes that he disclaims beneficial ownership of the trust shares except for any pecuniary interest.